Ayumi Pharmaceutical Holdings Acquired by GNI Group | Healthcare M&A Deal

GNI Group has agreed to acquire Ayumi Pharmaceutical Holdings, a pharmacy business in Japan, for $1.3 billion. GNI Group acquisitions are aimed at expanding commercial reach in Japan by adding Ayumi’s pain management portfolio and capabilities for introducing innovative therapies, biosimilars, and internally developed products. Ayumi Pharmaceutical Holdings operates in the Japanese pharmaceutical market, strengthening GNI Group’s healthcare M&A position across key therapeutic areas. The strategic acquisition is structured as a platform acquisition, with GNI Group planning to make Ayumi a wholly owned subsidiary and expecting combined fiscal 2026 revenue of about ¥65.2 billion. The deal is announced and valued at approximately ¥44.8 billion, with shareholders led by Blackstone selling their stake.